Disseminated histoplasmosis: A comparative study between patients with acquired immunodeficiency syndrome and non-human immunodeficiency virus-infected individuals

ABSTRACT : We studied 52 patients with disseminated histoplasmosis, 30 with the acquired immunodeficiency syndrome (AIDS) (cohort 1) and 22 not co-infected with the human immunodeficiency virus (cohort 2). Demographic, clinical, laboratory, mycologic findings, as well as antifungal therapy and highl...

Descripción completa

Detalles Bibliográficos
Autores: Tobón Orozco, Ángela María, Arango Arteaga, Myrtha, Bedout Gómez, Catalina de, Restrepo Moreno, Ángela, Agudelo Restrepo, Carlos Andrés, Rosero, Daniel Santiago, Ochoa Múnera, Juan Eugenio, Zuluaga Rodríguez, Alejandra, Sampedro, Jaime, Cano Restrepo, Luz Elena
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2005
País:Colombia
Institución:Universidad de Antioquia
Repositorio:Repositorio UdeA
Idioma:inglés
OAI Identifier:oai:bibliotecadigital.udea.edu.co:10495/20565
Acceso en línea:http://hdl.handle.net/10495/20565
Access Level:acceso abierto
Palabra clave:Histoplasmosis
Síndrome de Inmunodeficiencia Adquirida
Acquired Immunodeficiency Syndrome
Histoplasma
Descripción
Sumario:ABSTRACT : We studied 52 patients with disseminated histoplasmosis, 30 with the acquired immunodeficiency syndrome (AIDS) (cohort 1) and 22 not co-infected with the human immunodeficiency virus (cohort 2). Demographic, clinical, laboratory, mycologic findings, as well as antifungal therapy and highly active antiretroviral (HAART), were analyzed. Skin lesions were significantly higher in cohort 1 than in cohort2(P 0.001). Anemia, leukopenia, and an elevated erythrocyte sedimentation rate were also more pronounced in cohort 1 than in cohort 2 (P < 0.001). Histoplasma capsulatum was isolated more often in cohort 1 than in cohort 2 (P < 0.05) patients, but antibodies to H.capsulatum were detected more frequently in cohort 2 than in cohort 1 (P < 0.05). Itraconazole treatment was less effective in cohort 1 than in cohort 2 (P 0.012). In cohort 1 patients, HAART improved response to antifungals when compared with individuals not given HAART (P 0.003), who exhibited higher mortality rates (P 0.025). Cohort 1 patients who were given dual antifungal and anti-retroviral therapies responded as well as the non-HIV patients in cohort 2, who were treated only with itraconazole. These results indicate the need to promote restoration of the immune system in patients with AIDS and histoplasmosis.